ANNA-BIOSCIENCES
22.6.2021 15:02:10 CEST | Business Wire | Press release
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.
The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.
Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.
With today’s announcement, Anna Biosciences underscores both its initial successes in the lab and the successful patenting of the Syntem Platform. The company is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.
The Syntem Platform also shows strong promise for use against cancer and other pathogens. Research into the application of Syntem for oncological targets is currently underway. The resulting therapies could offer precision targeting, and the potential to mitigate side effects while being easier to administer to patients.
“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University in Ontario, Canada. “I’m extremely proud of our team, and the extraordinary effort of everyone involved at Anna Biosciences in the furthering of this technology.”
About Anna Biosciences
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to trigger synthetic immunity for COVID-19 and beyond.
Anna Biosciences will continue to develop the Syntem Platform modality for additional therapies for a range of diseases. The company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.
For more information, visit http://annabiosciences.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005353/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
TestMu AI Launches Official n8n partner integration, Bringing Real Browser Infrastructure to AI Agent Workflows18.6.2026 15:25:00 CEST | Press release
Developers can now access TestMu AI Browser Cloud directly from n8n workflows, enabling AI agents to operate across 3,000+ browser and operating system environments TestMu AI (formerly LambdaTest), the world's first Full-Stack Agentic AI Quality Engineering platform, today announced the launch of its official TestMu AI Agent partner integration for n8n, one of the fastest-growing workflow automation platforms for AI agents and enterprise automation. Available as an n8n verified and partnered Community Node, the TestMu AI Agent integration enables developers to connect AI agents and automated workflows to TestMu AI's Browser Cloud, providing access to more than 3,000 browser, operating system, and device environments without requiring single line of code as well. As organizations increasingly adopt AI agents for business automation, browser access has emerged as a critical capability. The new integration allows n8n users to equip their workflows with real cloud-hosted browsers capable o
Hytera Wins Two ICCA Awards and Showcases AI-Powered Innovations at CCW 202618.6.2026 15:00:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, concluded a successful participation at Critical Communications World (CCW) 2026 in London, showcasing its latest AI powered and mission critical communications innovations while receiving two awards at the International Critical Communications Awards (ICCAs) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618560904/en/ Hytera is recognized with two ICCA awards at CCW 2026 Held alongside CCW on June 16, the ICCAs ceremony recognized excellence across the global critical communications industry. Hytera received five nominations and won two awards, namely Best Hybrid Device for the Hytera PDC650 Dual-mode Rugged Radio and Best Use of Critical Communications in Transport for Hytera 5G MCX Solution for Xi'an Xianyang International Airport. The recognition highlights Hytera’s continued innovation in critical communications technologie
One NZ Future-Proofs Its Oracle Estate and Accelerates AI Innovation with Rimini Street18.6.2026 15:00:00 CEST | Press release
New Zealand’s leading digital services and connectivity provider partners with Rimini Street to stabilize mission-critical Oracle systems, solve complex interoperability challenges and fund AI transformation Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced One New Zealand (NZ) is leveraging Rimini Street’s support and interoperability solutions to ensure its critical Oracle systems remain secure, stable and reliable, while enabling the organization to redirect investment and talent toward modernization and AI initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618762726/en/ One NZ Future-Proofs Its Oracle Estate and Accelerates AI Innovation with Rimini Street One NZ serves 2 million customers with mobile, broadband and satellite solutions, connecting businesses and communities acro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom